Clinical Trial Update: A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

View source ↗

Summary

A completed clinical trial studied how hepatic impairment affects palbociclib-associated myelosuppression in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Status: COMPLETED